1.Development of selective androgen receptor modulators and their therapeutic applications.
Fang CHEN ; Gideon A RODAN ; Azi SCHMIDT
National Journal of Andrology 2002;8(3):162-168
Androgens control a broad range of physiological functions. The androgen receptor (AR), a steroid receptor that mediates the diverse biological actions of androgens, is a ligand inducible transcription factor. Abnormalities in the androgen signaling system result in many disturbances ranging from changes in gender determination and sexual development to psychiatric and emotional disorders. Androgen replacement therapy can improve many clinical conditions including hypogonadism and osteoporosis, but is limited by the lack of efficacious and safe therapeutic agents with easy delivery options. Recent progress in the area of gene regulation by steroid receptors and by selective receptor modulators provides an opportunity to examine if selective androgen receptor modulators (SARMs) could address some of the problems associated with current androgen therapy. Since the composition of the transcriptional initiation complex recruited by liganded AR determines the specificity of gene regulation, synthetic ligands aimed at initiating transcription of tissue and promoter specific genes offers hope for developing better androgen therapy. Establishment of assays that predict synthetic ligand activity is critical for SARM development. Advancement in high throughput compound screening and gene fingerprinting technologies, such as microarrays and proteomics, will facilitate and accelerate identification of effective SARMs.
Androgen Antagonists
;
pharmacology
;
Androgen Receptor Antagonists
;
Androgens
;
chemistry
;
metabolism
;
Chlormadinone Acetate
;
analogs & derivatives
;
pharmacology
;
Humans
;
Male
;
Receptors, Androgen
;
physiology
;
Receptors, Cytoplasmic and Nuclear
;
physiology
;
Testosterone Congeners
;
pharmacology
2.Effects of baicalin and other Chinese herbal monomer on androgen receptor mRNA expression in SZ95 sebocytes.
Qiang JU ; Xing-Ping YIN ; Ji-Hai SHI ; Xiao-Jing KANG ; Yan XIN ; Long-Qing XIA
Acta Academiae Medicinae Sinicae 2007;29(2):167-170
OBJECTIVETo determine the effects of Chinese herbal monomers such as baicalin, berberine, and matrine on the androgen receptor (AR) mRNA expression in SZ95 sebocytes in vitro and to explore the possible mechanism of using traditional Chinese medicines to treat acne.
METHODSSZ95 sebocytes were cultured and then treated with berberine, baicalin, matrine, and 13-cis-retinoic acid for 24 hours. Reverse transcription polymerase chain reaction was applied to detect the changes of AR.
RESULTAR mRNA was downregulated by 13-cis-retinoic acid of 1 x 10(-5) mol/L and 1 x 10(-6) mol/L, and by baicalin of 1 x 10(-4) mol/L (P < 0.05).
CONCLUSION13-cis-retinoic acid and baicalin may exert antiandrogenitic action by inhibiting AR mRNA expression in human sebocytes.
Androgen Antagonists ; pharmacology ; Cell Line ; Down-Regulation ; Drugs, Chinese Herbal ; pharmacology ; Flavonoids ; pharmacology ; Humans ; RNA, Messenger ; biosynthesis ; Receptors, Androgen ; biosynthesis ; genetics ; Skin ; cytology
3.Advances in the studies of androgen metabolism and de novo androgen synthesis in castration resistant prostate cancer.
Bin WANG ; Kai-Jie WU ; Da-Lin HE
National Journal of Andrology 2013;19(8):736-741
Prostate cancer generally relapses into castration resistant prostate cancer (CRPC) after androgen deprivation therapy, which may be associated with androgen metabolism, particularly de novo androgen synthesis apart from the amplification and mutation of androgen receptor and the activation of its signaling pathways. This article focuses on the advances in the studies of the changes in androgen metabolism and de novo androgen synthesis in CRPC as well as their possible mechanisms and clinical significance.
Androgen Antagonists
;
pharmacology
;
Androgens
;
biosynthesis
;
metabolism
;
Humans
;
Male
;
Orchiectomy
;
Prostate
;
metabolism
;
Prostatic Neoplasms, Castration-Resistant
;
metabolism
4.Proliferative response of human prostate cancer cell to hormone inhibited by androgen receptor antisense RNA.
Jun JIANG ; Luo-fu WANG ; Yu-hua FANG ; Feng-shuo JIN ; Wen-sheng JIN
Chinese Medical Journal 2004;117(5):684-688
BACKGROUNDThe failure of endocrine treatment for advanced prostate cancer might be related to aberrant activation of androgen receptor (AR). Prostate cancer cell line LNCaP contains AR that can be activated by androgen, estrogen and progesterone. This study was set to investigate the effects of antisense AR RNA on growth of LNCaP cultured in medium containing varied concentrations of R1881, 17beta-estradiol, and progesterone, respectively.
METHODSLNCaP cells transfected with antisense AR RNA retroviral vector pL-AR-SN were designated as LNCaPas-AR. LNCaP cells containing empty vector pLXSN served as LNCaPNeo. LNCaP and LNCaPNeo were taken as controls. In vitro cell growth assay, proliferative cells of LNCaP and tranfected LNCaPs were counted by typan staining when they cultured with synthetic androgen R1881, 17beta-estradiol, and progesterone, respectively.
RESULTSGrowth of LNCaPas-AR was inhibited significantly (P < 0.05) compared with that of LNCaP and LNCaPNeo at 1 nmol/L R1881, 10 nmol/L 17beta-estradiol, and 1 nmol/L progesterone, respectively. No difference was seen between LNCaP and LNCaPNeo (P > 0.05). Microscopic observation showed that LNCaP and LNCaPNeo cells grew well, but only few LNCaPas-AR cells were alive.
CONCLUSIONSOur observations indicate that antisense AR RNA retroviral vector pL-AR-SN could change androgen-independent characteristics of LNCaP cells, which might shed some novel insights into the treatment of androgen-independent prostate cancer.
Androgen Receptor Antagonists ; Cell Division ; drug effects ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Estradiol ; pharmacology ; Humans ; Male ; Metribolone ; antagonists & inhibitors ; pharmacology ; Progesterone ; antagonists & inhibitors ; pharmacology ; Prostatic Neoplasms ; pathology ; therapy ; RNA, Antisense ; therapeutic use ; Receptors, Androgen ; genetics
5.Antiandrogenic effects of cypermethrin and beta-cypermethrin.
Wei WU ; Jun ZHANG ; Wei ZHU ; Yi-fan ZHENG ; Hui-juan ZHU ; Mei XU ; Xin-qiang ZHU
Chinese Journal of Industrial Hygiene and Occupational Diseases 2008;26(4):193-197
OBJECTIVETo investigate the antiandrogenic activities of cypermethrin and beta-cypermethrin in vitro and in vivo.
METHODSTranscriptional activation assay based on MDA-kb2 cell was used to determine the antiandrogenic effect of cypermethrin and beta-cypermethrin in vitro. The cells were treated by 10(-8), 10(-7), 10(-6) and 10(-5) mol/L of cypermethrin and beta-cypermethrin with 1.0 nmol/L DHT at the same time. The effects of antagonism towards the androgenic receptor were studied. In in vivo assays, Hershberger assay was used to determine the antiandrogenic activities of cypermethrin and beta-cypermethrin. Six-week-old castrated male SD rats were administered by cypermethrin (7, 21 and 63 mg/kg) and beta-cypermethrin (6, 18 and 54 mg/kg). After 7-day treatments, all rats were euthanized and androgen-responsive tissues were excised and weighed respectively.
RESULTSThe in vitro experiments showed that 10(-6) and 10(-5) mol/L cypermethrin could inhibit significantly the antagonism activity towards the androgenic receptor of DHT. In in vivo tests, the weight of seminal vesicle, ventral prostate, dorsolateral prostate and preputial glands in the 63 mg/kg cypermethrin [(52.8 +/- 7.1), (42.4 +/- 8.9), (36.6 +/- 4.5) and (43.4 +/- 11.1) mg] decreased significantly compared with those in the control group. In 21 mg/kg cypermethrin treated group only the weights of ventral prostate and dorsolateral prostate decreased significantly, and in 7 mg/kg cypermethrin only the weight of dorsolateral prostate decreased (P < 0.05). For beta-cypermethrin, any antiandrogen effect in in vivo and in vitro experiments was not found in all the groups.
CONCLUSIONCypermethrin is a moderate antiandrogen that elicits antiandrogenic effects at least partly by antagonizing AR and beta-cypermethrin is not an antiandrogen in our experiments.
Androgen Antagonists ; pharmacology ; Animals ; Cells, Cultured ; Male ; Organ Size ; Prostate ; drug effects ; Pyrethrins ; pharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, Androgen ; drug effects ; Seminal Vesicles ; drug effects
6.Effect of testosterone on morphine withdrawal syndrome in rats.
Ali Reza Mohajjel NAYEBI ; Hassan REZAZADEH
Asian Journal of Andrology 2008;10(5):765-769
AIMTo determine whether testosterone is involved in morphine withdrawal syndrome (WS).
METHODSIn order to induce dependency, rats were treated with subcutaneous injection of morphine (days 1-2, 5 mg/kg; days 3-5, 7.5 mg/kg; days 6-8, 10 mg/kg), and after the last dose of morphine (day 8) WS was induced by intraperitoneal injection of naloxone (1 mg/kg). Wet dog shake (WDS), abdomen writhing (AW), and jumps (J) were recorded as indicators of WS.
RESULTSThe severity of WDS, AW, and J in male rats was greater than that in females. Accordingly, in 4-week castrated and flutamide-treated (10 mg/kg/day for 8 days, i.p.) male rats, WDS, AW, and J were significantly decreased compared to male control rats. Testosterone replacement therapy (10 mg/kg/day for 8 days, i.m.) in 4-week castrated rats restored the severity of WDS, AW, and J behaviors to the level of non-castrated male rats, whereas testosterone potentiated the WDS behavior in non-castrated male rats.
CONCLUSIONIt can be concluded that testosterone might be effectively involved in morphine WS.
Androgen Antagonists ; pharmacology ; Androgens ; pharmacology ; physiology ; Animals ; Behavior, Animal ; Female ; Flutamide ; pharmacology ; Male ; Morphine ; pharmacology ; Morphine Dependence ; physiopathology ; Naloxone ; pharmacology ; Narcotic Antagonists ; pharmacology ; Narcotics ; pharmacology ; Orchiectomy ; Rats ; Rats, Wistar ; Severity of Illness Index ; Substance Withdrawal Syndrome ; physiopathology ; Testosterone ; pharmacology ; physiology
7.Advances in researches on hormonal refractory prostate cancer.
National Journal of Andrology 2007;13(1):57-60
In China, the incidence of prostate cancer has been increasing in recent years. Hormonal therapy has been the mainstay of the therapeutic options for metastatic diseases for many years. But many metastatic tumors progress at a median of two to five years and become hormonal refractory prostate cancer (HRPC). This article summarizes in the advances of diagnostic criteria, molecular biological features, prediction markers, new therapeutic agents and further researches to be undertaken concerning HRPC.
Aged
;
Androgen Antagonists
;
pharmacology
;
Biomarkers, Tumor
;
analysis
;
Drug Resistance, Neoplasm
;
Humans
;
Male
;
Prostatic Neoplasms
;
diagnosis
;
drug therapy
;
pathology
8.Glutathione peroxidase activity in cell cultures from different regions of human epididymis.
Enrique CASTELLÓN ; Hernán RIOSECO ; Juan ROJAS ; Michel ROYER ; Eduardo SALAS ; Héctor CONTRERAS ; Christian HUIDOBRO
Asian Journal of Andrology 2005;7(1):33-37
AIMTo study the secretory activity and androgen regulation of glutathione peroxidase (GPx) in epithelial cell cultures from human epididymis.
METHODSTissue was obtained from patients undergoing therapeutic orchidectomy for prostatic cancer. Epithelial cell cultures were obtained from the caput, corpus and cauda epididymides. Enzymatic activity was measured in conditioned media by colorimetric methods in absence or presence of 1, 10 or 100 nmol/L testosterone. The effect of 1 micromol/L flutamide was also evaluated.
RESULTSGPx activity was higher in cultures from corpus and cauda than caput epididymidis. The presence of different concentrations of testosterone increase enzyme activity in cell cultures from all epididymal regions. Addition of flutamide reverses the androgen dependent increase of GPx activity.
CONCLUSIONGPx activity is secreted from human epididymal cells in a region dependent manner and is regulated by androgens.
Aged ; Androgen Antagonists ; pharmacology ; Cell Culture Techniques ; Epididymis ; enzymology ; Flutamide ; pharmacology ; Glutathione Peroxidase ; drug effects ; metabolism ; Humans ; Male ; Middle Aged ; Testosterone ; metabolism
9.Up-regulates the expression of maspin gene in prostate cancer cell line LNCaP.
Ping SHI ; Wei-Wen CHEN ; Xiao-Yan HU ; Chun-Xiao YU ; Peng-Ju ZHANG ; An-Li JIANG ; Jian-Ye ZHANG
Acta Pharmaceutica Sinica 2006;41(12):1152-1156
AIMTo study the effect of curcumin on the apoptosis of prostate cancer cell line LNCaP and regulation of expression of maspin gene.
METHODSMTT and DNA electrophoresis were used to examine the cell growth and apoptosis of prostate cancer cell line LNCaP after treated with different doses of curcumin. The expression of maspin gene at transcription level and translation level was also detected by RT-PCR and Western blotting. pGL3-maspin luciferase expression vector, containing 847 bp (- 764 -/+ 83) DNA of maspin gene 5' promoter region, was transient transfected into LNCaP cell. Through detecting the activity of luciferase, the effect of curcumin on the promoter of maspin was studied.
RESULTSCurcumin inhibited cell growth, induced the apoptosis and enhanced the expression of maspin gene in LNCaP cells.
CONCLUSIONCurcumin up-regulated expression of maspin gene in LNCaP cells through enhancing the transcription activity of promoter of maspin gene.
Androgen Receptor Antagonists ; Apoptosis ; drug effects ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Curcumin ; pharmacology ; Gene Expression Regulation, Neoplastic ; drug effects ; Humans ; Male ; Promoter Regions, Genetic ; Prostatic Neoplasms ; drug therapy ; genetics ; pathology ; RNA, Messenger ; analysis ; Receptors, Androgen ; genetics ; Serpins ; genetics
10.Hormone levels following surgical and medical castration: defining optimal androgen suppression.
Michael T SCHWEIZER ; Michael L HANCOCK ; Robert H GETZENBERG ; Evan Y YU
Asian Journal of Andrology 2018;20(4):405-406
Aged
;
Aged, 80 and over
;
Androgen Antagonists/pharmacology*
;
Androgens/blood*
;
Cohort Studies
;
Gonadotropin-Releasing Hormone/antagonists & inhibitors*
;
Hormones/blood*
;
Humans
;
Luteinizing Hormone/blood*
;
Male
;
Middle Aged
;
Orchiectomy
;
Prostatic Neoplasms/surgery*
;
Toremifene/therapeutic use*